MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping - Concepedia

Concepedia

Publication | Open Access

MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping

DOI Full Paper Access

37

Citations

25

References

2017

Year

S. Betty Yan, Suzane L. Um, Victoria L. Peek, Jennifer R. Stephens, Wei Zeng, Bruce W. Konicek, Ling Liu, Jason R. Manro, Volker Wacheck, Richard A. Walgren

Investigational New Drugs

References

	Year	Citations

Page 1